Compare Abbott Laboratories (ABT) vs CAVA Group Inc (CAVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs CAVA Group Inc — how do they compare? Abbott Laboratories trades at $108.87 (market cap $187.95B), while CAVA Group Inc trades at $69.77 (market cap $7.08B). The key difference: Abbott Laboratories is far larger — about 26.5× CAVA Group Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while CAVA Group Inc pays none. Which is the better fit depends on your goals.
| ABT | CAVA | |
|---|---|---|
Market Cap | $187.95B | $7.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $97.39 |
52-Week Low | $82.57 | $43.59 |
Enterprise Value | $214.96B | $7.23B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
CAVA trades at $69.68, up 13.15% with strong Q2 2026 earnings beats and 31.3% revenue growth. Technicals are bearish with support at $58, while fundamentals show high P/E of 108.59 but robust same-store sales. News highlights include menu innovation driving traffic and earnings outperformance.
Outlook is positive with a $89.75 consensus price target and 76% buy ratings, though valuation and net cash outflows pose risks. Growth momentum from new restaurants and consumer demand supports upside, but margin pressure and competition require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About CAVA Group Inc
CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.
Read more on CAVA →
